Crizotinib resistance conferred by BRAF V600E mutation in non-small cell lung cancer harboring an oncogenic ROS1 fusion

Shuang Ren; Sisi Huang; Xinqing Ye; Luhuai Feng; Yang Lu; Chaonan Zhou; Juan Zhao; Tingting He; Junwei Wang; Bixun Li

doi:10.1016/j.ctarc.2021.100377

Crizotinib resistance conferred by BRAF V600E mutation in non-small cell lung cancer harboring an oncogenic ROS1 fusion

Cancer Treat Res Commun. 2021:27:100377. doi: 10.1016/j.ctarc.2021.100377. Epub 2021 Apr 20.

Authors

Shuang Ren¹, Sisi Huang¹, Xinqing Ye², Luhuai Feng¹, Yang Lu¹, Chaonan Zhou¹, Juan Zhao³, Tingting He³, Junwei Wang³, Bixun Li⁴

Affiliations

¹ Department of General Internal Medicine, Guangxi Medical University Affiliated Cancer Hospital, No. 71 Hedi Road, Nanning, Guangxi, China.
² Department of Clinical Pathology, Guangxi Medical University Affiliated Cancer Hospital, No. 71 Hedi Road, Nanning, Guangxi, China.
³ OrigiMed, No.115 Xin Jun Huan Road, Minhang District, Shanghai, China.
⁴ Department of General Internal Medicine, Guangxi Medical University Affiliated Cancer Hospital, No. 71 Hedi Road, Nanning, Guangxi, China. Electronic address: libx_gmuch@hotmail.com.

PMID: 33945921
DOI: 10.1016/j.ctarc.2021.100377

Abstract

Non-small cell lung cancer (NSCLC) patients with oncogenic ROS1 rearrangements would inevitably develop drug resistance and disease progression after receiving targeted oncogene therapy. Here, we present a metastatic lung adenocarcinoma patient harboring a CD74-ROS1 fusion who initially responded to crizotinib and then developed resistance after acquiring a rarely reported BRAF V600E mutation.

Keywords: BRAF; Crizotinib; ROS1; Resistance.

Publication types

Case Reports

MeSH terms

Antigens, Differentiation, B-Lymphocyte / genetics
Antineoplastic Agents / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / genetics*
Crizotinib / therapeutic use*
Drug Resistance, Neoplasm / genetics*
Female
Histocompatibility Antigens Class II / genetics
Humans
Lung Neoplasms / drug therapy
Lung Neoplasms / genetics*
Middle Aged
Mutation
Oncogene Proteins, Fusion / genetics
Protein-Tyrosine Kinases / genetics
Proto-Oncogene Proteins / genetics
Proto-Oncogene Proteins B-raf / genetics*

Substances

Antigens, Differentiation, B-Lymphocyte
Antineoplastic Agents
Histocompatibility Antigens Class II
Oncogene Proteins, Fusion
Proto-Oncogene Proteins
invariant chain
Crizotinib
Protein-Tyrosine Kinases
ROS1 protein, human
BRAF protein, human
Proto-Oncogene Proteins B-raf